Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

A 2.5-Year Longitudinal Assessment of Naturalistic Driving in Preclinical Alzheimer's Disease.

Roe CM, Stout SH, Rajasekar G, Ances BM, Jones JM, Head D, Benzinger TLS, Williams MM, Davis JD, Ott BR, Warren DK, Babulal GM.

J Alzheimers Dis. 2019;68(4):1625-1633. doi: 10.3233/JAD-181242.

PMID:
30958365
2.

Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need.

Babulal GM, Quiroz YT, Albensi BC, Arenaza-Urquijo E, Astell AJ, Babiloni C, Bahar-Fuchs A, Bell J, Bowman GL, Brickman AM, Chételat G, Ciro C, Cohen AD, Dilworth-Anderson P, Dodge HH, Dreux S, Edland S, Esbensen A, Evered L, Ewers M, Fargo KN, Fortea J, Gonzalez H, Gustafson DR, Head E, Hendrix JA, Hofer SM, Johnson LA, Jutten R, Kilborn K, Lanctôt KL, Manly JJ, Martins RN, Mielke MM, Morris MC, Murray ME, Oh ES, Parra MA, Rissman RA, Roe CM, Santos OA, Scarmeas N, Schneider LS, Schupf N, Sikkes S, Snyder HM, Sohrabi HR, Stern Y, Strydom A, Tang Y, Terrera GM, Teunissen C, Melo van Lent D, Weinborn M, Wesselman L, Wilcock DM, Zetterberg H, O'Bryant SE; International Society to Advance Alzheimer's Research and Treatment, Alzheimer's Association.

Alzheimers Dement. 2019 Feb;15(2):292-312. doi: 10.1016/j.jalz.2018.09.009. Epub 2018 Dec 13.

3.

Depression and Alzheimer's Disease Biomarkers Predict Driving Decline.

Babulal GM, Chen S, Williams MM, Trani JF, Bakhshi P, Chao GL, Stout SH, Fagan AM, Benzinger TLS, Holtzman DM, Morris JC, Roe CM.

J Alzheimers Dis. 2018;66(3):1213-1221. doi: 10.3233/JAD-180564.

4.

Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers.

Roe CM, Ances BM, Head D, Babulal GM, Stout SH, Grant EA, Hassenstab J, Xiong C, Holtzman DM, Benzinger TLS, Schindler SE, Fagan AM, Morris JC.

Brain. 2018 Nov 1;141(11):3233-3248. doi: 10.1093/brain/awy244.

PMID:
30304397
5.

Loss of white matter integrity reflects tau accumulation in Alzheimer disease defined regions.

Strain JF, Smith RX, Beaumont H, Roe CM, Gordon BA, Mishra S, Adeyemo B, Christensen JJ, Su Y, Morris JC, Benzinger TLS, Ances BM.

Neurology. 2018 Jul 24;91(4):e313-e318. doi: 10.1212/WNL.0000000000005864. Epub 2018 Jun 29.

PMID:
29959265
6.

Using the A/T/N Framework to Examine Driving in Preclinical AD.

Roe CM, Babulal GM, Stout SH, Ott BR, Carr DB, Williams MM, Benzinger TLS, Fagan AM, Holtzman DM, Ances BM, Morris JC.

Geriatrics (Basel). 2018 Jun;3(2). pii: 23. doi: 10.3390/geriatrics3020023. Epub 2018 May 2. No abstract available.

7.

Driving Outcomes among Older Adults: A Systematic Review on Racial and Ethnic Differences over 20 Years.

Babulal GM, Williams MM, Stout SH, Roe CM.

Geriatrics (Basel). 2018 Mar;3(1). pii: 12. doi: 10.3390/geriatrics3010012. Epub 2018 Mar 20.

8.

Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease.

Mattsson N, Groot C, Jansen WJ, Landau SM, Villemagne VL, Engelborghs S, Mintun MM, Lleo A, Molinuevo JL, Jagust WJ, Frisoni GB, Ivanoiu A, Chételat G, Resende de Oliveira C, Rodrigue KM, Kornhuber J, Wallin A, Klimkowicz-Mrowiec A, Kandimalla R, Popp J, Aalten PP, Aarsland D, Alcolea D, Almdahl IS, Baldeiras I, van Buchem MA, Cavedo E, Chen K, Cohen AD, Förster S, Fortea J, Frederiksen KS, Freund-Levi Y, Gill KD, Gkatzima O, Grimmer T, Hampel H, Herukka SK, Johannsen P, van Laere K, de Leon MJ, Maier W, Marcusson J, Meulenbroek O, Møllergård HM, Morris JC, Mroczko B, Nordlund A, Prabhakar S, Peters O, Rami L, Rodríguez-Rodríguez E, Roe CM, Rüther E, Santana I, Schröder J, Seo SW, Soininen H, Spiru L, Stomrud E, Struyfs H, Teunissen CE, Verhey FRJ, Vos SJB, van Waalwijk van Doorn LJC, Waldemar G, Wallin ÅK, Wiltfang J, Vandenberghe R, Brooks DJ, Fladby T, Rowe CC, Drzezga A, Verbeek MM, Sarazin M, Wolk DA, Fleisher AS, Klunk WE, Na DL, Sánchez-Juan P, Lee DY, Nordberg A, Tsolaki M, Camus V, Rinne JO, Fagan AM, Zetterberg H, Blennow K, Rabinovici GD, Hansson O, van Berckel BNM, van der Flier WM, Scheltens P, Visser PJ, Ossenkoppele R.

Alzheimers Dement. 2018 Jul;14(7):913-924. doi: 10.1016/j.jalz.2018.02.009. Epub 2018 Mar 28.

PMID:
29601787
9.

Alzheimer Disease Biomarkers and Driving in Clinically Normal Older Adults: Role of Spatial Navigation Abilities.

Allison S, Babulal GM, Stout SH, Barco PP, Carr DB, Fagan AM, Morris JC, Roe CM, Head D.

Alzheimer Dis Assoc Disord. 2018 Apr-Jun;32(2):101-106. doi: 10.1097/WAD.0000000000000257.

10.

Political Ideology, Confidence in Science, and Participation in Alzheimer Disease Research Studies.

Gabel M, Gooblar J, Roe CM, Selsor NJ, Morris JC.

Alzheimer Dis Assoc Disord. 2018 Jul-Sep;32(3):179-184. doi: 10.1097/WAD.0000000000000244.

PMID:
29351092
11.

Driving cessation over a 24-year period: Dementia severity and cerebrospinal fluid biomarkers.

Stout SH, Babulal GM, Ma C, Carr DB, Head DM, Grant EA, Williams MM, Holtzman DM, Fagan AM, Morris JC, Roe CM.

Alzheimers Dement. 2018 May;14(5):610-616. doi: 10.1016/j.jalz.2017.11.011. Epub 2018 Jan 10.

12.

Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia.

Jansen WJ, Ossenkoppele R, Tijms BM, Fagan AM, Hansson O, Klunk WE, van der Flier WM, Villemagne VL, Frisoni GB, Fleisher AS, Lleó A, Mintun MA, Wallin A, Engelborghs S, Na DL, Chételat G, Molinuevo JL, Landau SM, Mattsson N, Kornhuber J, Sabri O, Rowe CC, Parnetti L, Popp J, Fladby T, Jagust WJ, Aalten P, Lee DY, Vandenberghe R, Resende de Oliveira C, Kapaki E, Froelich L, Ivanoiu A, Gabryelewicz T, Verbeek MM, Sanchez-Juan P, Hildebrandt H, Camus V, Zboch M, Brooks DJ, Drzezga A, Rinne JO, Newberg A, de Mendonça A, Sarazin M, Rabinovici GD, Madsen K, Kramberger MG, Nordberg A, Mok V, Mroczko B, Wolk DA, Meyer PT, Tsolaki M, Scheltens P, Verhey FRJ, Visser PJ; Amyloid Biomarker Study Group, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BNM, Blennow K, van Buchem MA, Cavedo E, Chen K, Chipi E, Cohen AD, Förster S, Fortea J, Frederiksen KS, Freund-Levi Y, Gkatzima O, Gordon MF, Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka SK, Johannsen P, Klimkowicz-Mrowiec A, Köhler S, Koglin N, van Laere K, de Leon M, Lisetti V, Maier W, Marcusson J, Meulenbroek O, Møllergård HM, Morris JC, Nordlund A, Novak GP, Paraskevas GP, Perera G, Peters O, Ramakers IHGB, Rami L, Rodríguez-Rodríguez E, Roe CM, Rot U, Rüther E, Santana I, Schröder J, Seo SW, Soininen H, Spiru L, Stomrud E, Struyfs H, Teunissen CE, Vos SJB, van Waalwijk van Doorn LJC, Waldemar G, Wallin ÅK, Wiltfang J, Zetterberg H.

JAMA Psychiatry. 2018 Jan 1;75(1):84-95. doi: 10.1001/jamapsychiatry.2017.3391. Erratum in: JAMA Psychiatry. 2018 Mar 1;75(3):303.

13.

Tau and Amyloid Positron Emission Tomography Imaging Predict Driving Performance Among Older Adults with and without Preclinical Alzheimer's Disease.

Roe CM, Babulal GM, Mishra S, Gordon BA, Stout SH, Ott BR, Carr DB, Ances BM, Morris JC, Benzinger TLS.

J Alzheimers Dis. 2018;61(2):509-513. doi: 10.3233/JAD-170521.

14.

Neuropsychiatric Symptoms and Alzheimer's Disease Biomarkers Predict Driving Decline: Brief Report.

Babulal GM, Stout SH, Head D, Holtzman DM, Fagan AM, Morris JC, Roe CM.

J Alzheimers Dis. 2017;58(3):675-680. doi: 10.3233/JAD-170067.

15.

Preclinical Alzheimer's disease and longitudinal driving decline.

Roe CM, Babulal GM, Head DM, Stout SH, Vernon EK, Ghoshal N, Garland B, Barco PP, Williams MM, Johnson A, Fierberg R, Fague MS, Xiong C, Mormino E, Grant EA, Holtzman DM, Benzinger TLS, Fagan AM, Ott BR, Carr DB, Morris JC.

Alzheimers Dement (N Y). 2017 Jan;3(1):74-82. doi: 10.1016/j.trci.2016.11.006.

16.

A Naturalistic Study of Driving Behavior in Older Adults and Preclinical Alzheimer Disease: A Pilot Study.

Babulal GM, Stout SH, Benzinger TLS, Ott BR, Carr DB, Webb M, Traub CM, Addison A, Morris JC, Warren DK, Roe CM.

J Appl Gerontol. 2019 Feb;38(2):277-289. doi: 10.1177/0733464817690679. Epub 2017 Jan 29.

PMID:
28380718
17.

Brain amyloid in preclinical Alzheimer's disease is associated with increased driving risk.

Ott BR, Jones RN, Noto RB, Yoo DC, Snyder PJ, Bernier JN, Carr DB, Roe CM.

Alzheimers Dement (Amst). 2016 Nov 29;6:136-142. doi: 10.1016/j.dadm.2016.10.008. eCollection 2017.

18.

Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease.

Day GS, Lim TS, Hassenstab J, Goate AM, Grant EA, Roe CM, Cairns NJ, Morris JC.

Neurology. 2017 Mar 28;88(13):1273-1281. doi: 10.1212/WNL.0000000000003770. Epub 2017 Feb 24.

19.

Association of Functional Impairments and Co-Morbid Conditions with Driving Performance among Cognitively Normal Older Adults.

Carr DB, Barco PP, Babulal GM, Stout SH, Johnson AM, Xiong C, Morris JC, Roe CM.

PLoS One. 2016 Dec 22;11(12):e0167751. doi: 10.1371/journal.pone.0167751. eCollection 2016.

20.

Creating a driving profile for older adults using GPS devices and naturalistic driving methodology.

Babulal GM, Traub CM, Webb M, Stout SH, Addison A, Carr DB, Ott BR, Morris JC, Roe CM.

Version 2. F1000Res. 2016 Sep 26 [revised 2016 Jan 1];5:2376. eCollection 2016.

21.

The interaction of sleep and amyloid deposition on cognitive performance.

Molano JRV, Roe CM, Ju YS.

J Sleep Res. 2017 Jun;26(3):288-292. doi: 10.1111/jsr.12474. Epub 2016 Dec 1.

22.

Genetic Comparison of Symptomatic and Asymptomatic Persons With Alzheimer Disease Neuropathology.

Monsell SE, Mock C, Fardo DW, Bertelsen S, Cairns NJ, Roe CM, Ellingson SR, Morris JC, Goate AM, Kukull WA.

Alzheimer Dis Assoc Disord. 2017 Jul-Sep;31(3):232-238. doi: 10.1097/WAD.0000000000000179.

23.

Development and interval testing of a naturalistic driving methodology to evaluate driving behavior in clinical research.

Babulal GM, Addison A, Ghoshal N, Stout SH, Vernon EK, Sellan M, Roe CM.

Version 2. F1000Res. 2016 Jul 15 [revised 2016 Jan 1];5:1716. eCollection 2016.

24.

Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels.

Babulal GM, Ghoshal N, Head D, Vernon EK, Holtzman DM, Benzinger TLS, Fagan AM, Morris JC, Roe CM.

Am J Geriatr Psychiatry. 2016 Nov;24(11):1095-1104. doi: 10.1016/j.jagp.2016.04.004. Epub 2016 Apr 19.

25.

Phenotypic Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease: A Single-Family Case-Control Study.

Day GS, Musiek ES, Roe CM, Norton J, Goate AM, Cruchaga C, Cairns NJ, Morris JC.

JAMA Neurol. 2016 Sep 1;73(9):1125-32. doi: 10.1001/jamaneurol.2016.1236.

26.

Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals.

Roe CM, Barco PP, Head DM, Ghoshal N, Selsor N, Babulal GM, Fierberg R, Vernon EK, Shulman N, Johnson A, Fague S, Xiong C, Grant EA, Campbell A, Ott BR, Holtzman DM, Benzinger TL, Fagan AM, Carr DB, Morris JC.

Alzheimer Dis Assoc Disord. 2017 Jan-Mar;31(1):69-72. doi: 10.1097/WAD.0000000000000154.

27.

Cerebrospinal Fluid Biomarkers and Reserve Variables as Predictors of Future "Non-Cognitive" Outcomes of Alzheimer's Disease.

Ingber AP, Hassenstab J, Fagan AM, Benzinger TL, Grant EA, Holtzman DM, Morris JC, Roe CM.

J Alzheimers Dis. 2016;52(3):1055-64. doi: 10.3233/JAD-150478.

28.

Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research Results.

Gooblar J, Roe CM, Selsor NJ, Gabel MJ, Morris JC.

JAMA Neurol. 2015 Dec;72(12):1484-90. doi: 10.1001/jamaneurol.2015.2875.

29.

Neuropsychological Markers of Cognitive Decline in Persons With Alzheimer Disease Neuropathology.

Hassenstab J, Monsell SE, Mock C, Roe CM, Cairns NJ, Morris JC, Kukull W.

J Neuropathol Exp Neurol. 2015 Nov;74(11):1086-92. doi: 10.1097/NEN.0000000000000254.

30.

Interrater Reliability of the Record of Driving Errors (RODE).

Barco PP, Carr DB, Rutkoski K, Xiong C, Roe CM.

Am J Occup Ther. 2015 Mar-Apr;69(2):6902350020p1-6. doi: 10.5014/ajot.2015.013128.

31.

The effects of white matter hyperintensities and amyloid deposition on Alzheimer dementia.

Gordon BA, Najmi S, Hsu P, Roe CM, Morris JC, Benzinger TL.

Neuroimage Clin. 2015 Apr 30;8:246-52. doi: 10.1016/j.nicl.2015.04.017. eCollection 2015.

32.

Adults Aged 65 and Older Use Potentially Distracting Electronic Devices While Driving.

Vernon EK, Babulal GM, Head D, Carr D, Ghoshal N, Barco PP, Morris JC, Roe CM.

J Am Geriatr Soc. 2015 Jun;63(6):1251-4. doi: 10.1111/jgs.13499. No abstract available.

33.

Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis.

Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BN, Scheltens P, Visser PJ; Amyloid PET Study Group, Verfaillie SC, Zwan MD, Adriaanse SM, Lammertsma AA, Barkhof F, Jagust WJ, Miller BL, Rosen HJ, Landau SM, Villemagne VL, Rowe CC, Lee DY, Na DL, Seo SW, Sarazin M, Roe CM, Sabri O, Barthel H, Koglin N, Hodges J, Leyton CE, Vandenberghe R, van Laere K, Drzezga A, Forster S, Grimmer T, Sánchez-Juan P, Carril JM, Mok V, Camus V, Klunk WE, Cohen AD, Meyer PT, Hellwig S, Newberg A, Frederiksen KS, Fleisher AS, Mintun MA, Wolk DA, Nordberg A, Rinne JO, Chételat G, Lleo A, Blesa R, Fortea J, Madsen K, Rodrigue KM, Brooks DJ.

JAMA. 2015 May 19;313(19):1939-49. doi: 10.1001/jama.2015.4669.

34.

Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis.

Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, Visser PJ; Amyloid Biomarker Study Group, Aalten P, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BN, Bibeau K, Blennow K, Brooks DJ, van Buchem MA, Camus V, Cavedo E, Chen K, Chetelat G, Cohen AD, Drzezga A, Engelborghs S, Fagan AM, Fladby T, Fleisher AS, van der Flier WM, Ford L, Förster S, Fortea J, Foskett N, Frederiksen KS, Freund-Levi Y, Frisoni GB, Froelich L, Gabryelewicz T, Gill KD, Gkatzima O, Gómez-Tortosa E, Gordon MF, Grimmer T, Hampel H, Hausner L, Hellwig S, Herukka SK, Hildebrandt H, Ishihara L, Ivanoiu A, Jagust WJ, Johannsen P, Kandimalla R, Kapaki E, Klimkowicz-Mrowiec A, Klunk WE, Köhler S, Koglin N, Kornhuber J, Kramberger MG, Van Laere K, Landau SM, Lee DY, de Leon M, Lisetti V, Lleó A, Madsen K, Maier W, Marcusson J, Mattsson N, de Mendonça A, Meulenbroek O, Meyer PT, Mintun MA, Mok V, Molinuevo JL, Møllergård HM, Morris JC, Mroczko B, Van der Mussele S, Na DL, Newberg A, Nordberg A, Nordlund A, Novak GP, Paraskevas GP, Parnetti L, Perera G, Peters O, Popp J, Prabhakar S, Rabinovici GD, Ramakers IH, Rami L, Resende de Oliveira C, Rinne JO, Rodrigue KM, Rodríguez-Rodríguez E, Roe CM, Rot U, Rowe CC, Rüther E, Sabri O, Sanchez-Juan P, Santana I, Sarazin M, Schröder J, Schütte C, Seo SW, Soetewey F, Soininen H, Spiru L, Struyfs H, Teunissen CE, Tsolaki M, Vandenberghe R, Verbeek MM, Villemagne VL, Vos SJ, van Waalwijk van Doorn LJ, Waldemar G, Wallin A, Wallin ÅK, Wiltfang J, Wolk DA, Zboch M, Zetterberg H.

JAMA. 2015 May 19;313(19):1924-38. doi: 10.1001/jama.2015.4668.

35.

Clinical Features of Alzheimer Disease With and Without Lewy Bodies.

Chung EJ, Babulal GM, Monsell SE, Cairns NJ, Roe CM, Morris JC.

JAMA Neurol. 2015 Jul;72(7):789-96. doi: 10.1001/jamaneurol.2015.0606.

36.

Cognitive impairments and mood disruptions negatively impact instrumental activities of daily living performance in the first three months after a first stroke.

Babulal GM, Huskey TN, Roe CM, Goette SA, Connor LT.

Top Stroke Rehabil. 2015 Apr;22(2):144-51. doi: 10.1179/1074935714Z.0000000012. Epub 2015 Mar 2.

PMID:
25936546
37.

"Noncognitive" symptoms of early Alzheimer disease: a longitudinal analysis.

Masters MC, Morris JC, Roe CM.

Neurology. 2015 Feb 10;84(6):617-22.

38.

Pathological correlates of white matter hyperintensities on magnetic resonance imaging.

Shim YS, Yang DW, Roe CM, Coats MA, Benzinger TL, Xiong C, Galvin JE, Cairns NJ, Morris JC.

Dement Geriatr Cogn Disord. 2015;39(1-2):92-104. doi: 10.1159/000366411. Epub 2014 Nov 8.

39.

Increased susceptibility to oxidative death of lymphocytes from Alzheimer patients correlates with dementia severity.

Ponce DP, Salech F, SanMartin CD, Silva M, Xiong C, Roe CM, Henriquez M, Quest AF, Behrens MI.

Curr Alzheimer Res. 2014;11(9):892-8.

40.

Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology.

Monsell SE, Mock C, Hassenstab J, Roe CM, Cairns NJ, Morris JC, Kukull W.

Neurology. 2014 Jul 29;83(5):434-40. doi: 10.1212/WNL.0000000000000650. Epub 2014 Jun 20.

41.

The effect of APOE ε4 allele on cholinesterase inhibitors in patients with Alzheimer disease: evaluation of the feasibility of resting state functional connectivity magnetic resonance imaging.

Wang L, Day J, Roe CM, Brier MR, Thomas JB, Benzinger TL, Morris JC, Ances BM.

Alzheimer Dis Assoc Disord. 2014 Apr-Jun;28(2):122-7. doi: 10.1097/WAD.0b013e318299d096.

42.

CSF biomarkers of Alzheimer disease: "noncognitive" outcomes.

Roe CM, Fagan AM, Grant EA, Holtzman DM, Morris JC.

Neurology. 2013 Dec 3;81(23):2028-31. doi: 10.1212/01.wnl.0000436940.78152.05. Epub 2013 Nov 8.

43.

Exploration of 100 commonly used drugs and supplements on cognition in older adults.

Obermann KR, Morris JC, Roe CM.

Alzheimers Dement. 2013 Nov;9(6):724-32. doi: 10.1016/j.jalz.2012.12.002. Epub 2013 Aug 15.

44.

AD and cancer: epidemiology makes for strange bedfellows.

Roe CM, Behrens MI.

Neurology. 2013 Jul 23;81(4):310-1. doi: 10.1212/WNL.0b013e31829c5f16. Epub 2013 Jul 10. No abstract available.

PMID:
23843465
45.

Preclinical Alzheimer disease and risk of falls.

Stark SL, Roe CM, Grant EA, Hollingsworth H, Benzinger TL, Fagan AM, Buckles VD, Morris JC.

Neurology. 2013 Jul 30;81(5):437-43. doi: 10.1212/WNL.0b013e31829d8599. Epub 2013 Jun 26.

46.

Physical activity and cognitive trajectories in cognitively normal adults: the adult children study.

Pizzie R, Hindman H, Roe CM, Head D, Grant E, Morris JC, Hassenstab JJ.

Alzheimer Dis Assoc Disord. 2014 Jan-Mar;28(1):50-7. doi: 10.1097/WAD.0b013e31829628d4.

47.

Mild physical impairment predicts future diagnosis of dementia of the Alzheimer's type.

Wilkins CH, Roe CM, Morris JC, Galvin JE.

J Am Geriatr Soc. 2013 Jul;61(7):1055-9. doi: 10.1111/jgs.12255. Epub 2013 May 6.

48.

Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology.

Monsell SE, Mock C, Roe CM, Ghoshal N, Morris JC, Cairns NJ, Kukull W.

Neurology. 2013 Jun 4;80(23):2121-9. doi: 10.1212/WNL.0b013e318295d7a1. Epub 2013 May 3.

49.

Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later.

Roe CM, Fagan AM, Grant EA, Hassenstab J, Moulder KL, Maue Dreyfus D, Sutphen CL, Benzinger TL, Mintun MA, Holtzman DM, Morris JC.

Neurology. 2013 May 7;80(19):1784-91. doi: 10.1212/WNL.0b013e3182918ca6. Epub 2013 Apr 10.

50.

Alzheimer disease: before the diagnosis.

Roe CM, Rentz DM.

Neurology. 2013 Mar 26;80(13):e148-9. doi: 10.1212/WNL.0b013e31828cade3. No abstract available.

PMID:
23530160

Supplemental Content

Support Center